Related Experiment Video
Updated: Aug 16, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor
Tasia Amelia1, Aderian Novito Setiawan1, Rahmana Emran Kartasasmita1
1School of Pharmacy, Bandung Institute of Technology, Jalan Ganesha 10, Bandung 40132, Indonesia.
Abstract:
Epidermal growth factor receptor (EGFR) resistance to tyrosine kinase inhibitors can cause low survival rates in mutation-positive non-small cell lung cancer patients. It is necessary to predict new mutations in the development of more potent EGFR inhibitors since classical and rare mutations observed were known to affect the effectiveness of the therapy. Therefore, this research aimed to perform alanine mutagenesis scanning on ATP binding site residues without COSMIC data, followed by molecular dynamic simulations to determine their molecular interactions with ATP and erlotinib compared to wild-type complexes. Based on the result, eight mutations were found to cause changes in the binding energy of the ATP analogue to become more negative. These included G779A, Q791A, L792A, R841A, N842A, V843A, I853A, and D855A, which were predicted to enhance the affinity of ATP and reduce the binding ability of inhibitors with the same interaction site. Erlotinib showed more positive energy among G779A, Q791A, I853A, and D855A, due to their weaker binding energy than ATP. These four mutations could be anticipated in the development of the next inhibitor to overcome the incidence of resistance in lung cancer patients.
Insights
New mutations in epidermal growth factor receptor (EGFR) can cause resistance to lung cancer therapies. This study identified four specific EGFR mutations that enhance ATP binding, potentially guiding the development of next-generation inhibitors for non-small cell lung cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Resistance to tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) significantly reduces patient survival.
- Understanding novel resistance mutations is crucial for developing more effective EGFR inhibitors.
Purpose of the Study:
- To investigate the impact of alanine mutagenesis scanning on EGFR ATP binding site residues on molecular interactions with ATP and erlotinib.
- To predict new mutations that confer resistance to EGFR inhibitors.
Main Methods:
- Alanine mutagenesis scanning of EGFR ATP binding site residues.
- Molecular dynamic simulations to assess binding energies and interactions with ATP and erlotinib.
- Comparison with wild-type EGFR complexes.
Main Results:
- Eight mutations (G779A, Q791A, L792A, R841A, N842A, V843A, I853A, D855A) altered binding energy, favoring ATP binding.
- Mutations G779A, Q791A, I853A, and D855A showed weaker binding to erlotinib compared to ATP.
- These four mutations are predicted to enhance ATP affinity and reduce inhibitor binding efficacy.
Conclusions:
- Identified specific EGFR mutations that enhance ATP binding and reduce erlotinib efficacy.
- These findings provide insights for designing next-generation EGFR inhibitors to overcome treatment resistance in NSCLC.
More Related Videos
06:50Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
Published on: January 26, 2024
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:49Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...